Logo

Developing the next evolution of oncolytic immunotherapy for patients with advanced cancers.

Our Science

Genetically engineered oncolytic immunotherapy with a multiple-pronged attack on cancer.

Learn More

June 4, 2022

CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

May 16, 2022

CG Oncology Presents Additional Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

April 13, 2022

CG Oncology Presents Interim Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

  • About
    • Overview
    • Management
    • Board of Directors
    • Contact
  • Pipeline
    • Overview
    • CG0070
    • CG0161
  • Technology
    • Overview
    • Publications
  • News
    • Press Releases
    • Conferences & Media
    • Media Contact
  • Careers
    • Overview
  • Contact
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
    • Contact
  • Pipeline
    • Overview
    • CG0070
    • CG0161
  • Technology
    • Overview
    • Publications
  • News
    • Press Releases
    • Conferences & Media
    • Media Contact
  • Careers
    • Overview
  • Contact
  • LinkedIn
  • Twitter
  • Youtube
© 2022 CG Oncology, Inc. All rights reserved.
  • LinkedIn
  • Twitter
  • Youtube